Skip to main content

AREXVY (GlaxoSmithKline Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
166 (255 working days)
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein
Registration type

AREXVY is indicated for active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

The use of this vaccine should be in accordance with official recommendations.

Help us improve the Therapeutic Goods Administration site